Now showing items 1-3 of 3

    • Combining NK cells and mAb9.2.27 to combat NG2-dependent and anti-inflammatory signals in glioblastoma 

      Kmiecik, Justyna; Gras Navarro, Andrea; Poli, Aurélie; Planaguma, Jesus; Zimmer, Jacques; Chekenya, Martha (Taylor & Francis, 2014)
      Glioblastoma is a deadly brain cancer with limited treatment options. Targeting chondroitin sulfate proteoglycan 4 (CSPG4, best known as NG2) with the monoclonal antibody mAb9.2.27 and activated natural killer (NK) cells ...
      Journal article
    • Natural killer cells in intracranial neoplasms: presence and therapeutic efficacy against brain tumours 

      Kmiecik, Justyna; Zimmer, Jacques; Chekenya, Martha (Springer, 2014-01)
      Natural killer (NK) cells are lymphocytes that play an important role in anti-tumour immunity. Their potential against brain cancer has been demonstrated in vitro and in vivo, both as a direct anti-tumour agent and in ...
      Peer reviewedJournal article
    • Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival 

      Poli, Aurélie; Wang, Jian; Domingues, Olivia; Planagumà, Jesús; Yan, Tao; Rygh, Cecilie Brekke; Skaftnesmo, Kai Ove; Thorsen, Frits Alan; McCormack, Emmet; Hentges, François; Pedersen, Paal-Henning; Zimmer, Jacques; Enger, Per Øyvind; Chekenya, Martha (Impact Journals, 2013-09-09)
      Glioblastoma (GBM) is the most malignant brain tumor where patients’ survival is only 14.6 months, despite multimodal therapy with debulking surgery, concurrent chemotherapy and radiotherapy. There is an urgent, unmet ...
      Journal article